#4-06E. Streamlining RA Therapy: The 2025 EULAR Recommendations Update (Ann Rheum Dis, 2026)

In daily rheumatology practice, determining the next therapeutic step after a patient fails initial therapy for rheumatoid arthritis (RA) can be a significant clinical challenge. This episode explores the 2025 update to the European Alliance of Associations for Rheumatology (EULAR) guidelines for managing RA with synthetic and biologic disease-modifying antirheumatic drugs (DMARDs). Based on comprehensive systematic literature reviews, this paper outlines five overarching principles and nine streamlined recommendations. The most pivotal clinical shift in this update is the elimination of prognostic risk-factor stratification upon the failure of initial methotrexate and short-term glucocorticoid therapy. The task force now recommends progressing directly to the addition of a biologic DMARD or a targeted synthetic DMARD, such as a JAK inhibitor. However, when critically appraising these guidelines, clinicians must note that no new randomized controlled trials regarding the cardiovascular and malignancy risks of JAK inhibitors were available for this update. Therefore, stringent individual risk assessment remains imperative before prescribing these agents. Ultimately, this updated framework equips physicians with a simplified, evidence-based algorithm to confidently navigate the multitude of available advanced therapies, making it an indispensable tool for optimizing treat-to-target strategies in everyday clinical care.

Citation: Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Annals of the Rheumatic Diseases. 2026. DOI: 10.1016/j.ard.2026.01.023

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.